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Abstract
Annual losses of honey bee colonies remain high and pesticide exposure is one possible
cause. Dangerous combinations of pesticides, plant-produced compounds and antibiotics
added to hives may cause or contribute to losses, but it is very difficult to test the many com-
binations of those compounds that bees encounter. We propose a mechanism-based strat-
egy for simplifying the assessment of combinations of compounds, focusing here on
compounds that interact with xenobiotic handling ABC transporters. We evaluate the use of
ivermectin as a model substrate for these transporters. Compounds that increase sensitivity
of bees to ivermectin may be inhibiting key transporters. We show that several compounds
commonly encountered by honey bees (fumagillin, Pristine, quercetin) significantly
increased honey bee mortality due to ivermectin and significantly reduced the LC50 of iver-
mectin suggesting that they may interfere with transporter function. These inhibitors also
significantly increased honey bees sensitivity to the neonicotinoid insecticide acetamiprid.
This mechanism-based strategy may dramatically reduce the number of tests needed to
assess the possibility of adverse combinations among pesticides. We also demonstrate an
in vivo transporter assay that provides physical evidence of transporter inhibition by tracking
the dynamics of a fluorescent substrate of these transporters (Rhodamine B) in bee tissues.
Significantly more Rhodamine B remains in the head and hemolymph of bees pretreated
with higher concentrations of the transporter inhibitor verapamil. Mechanism-based strate-
gies for simplifying the assessment of adverse chemical interactions such as described
here could improve our ability to identify those combinations that pose significantly greater
risk to bees and perhaps improve the risk assessment protocols for honey bees and similar
sensitive species.
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Introduction
Annual losses of honey bee colonies, including overwintering losses, remain high, ranging
between 34 and 45% in recent surveys [1, 2]. Various factors have been proposed to explain
losses, including parasites and pathogens (particularly the parasitic mite Varroa destructor),
poor nutrition, and pesticides [3]. The role of pesticides as a factor in increased mortality rates
has received considerable attention [4–7]. Managed honey bee colonies are exposed to poten-
tially dangerous pesticides in two distinct ways, through in-hive miticides to control parasites
[7, 8] and through the foraging activity of adult bees who collect pollen and nectar which has
been contaminated by environmental toxins, including agricultural pesticides [9, 10]. While
there are notable examples of acute colony mortality associated with pesticide exposure,
especially recently in planting-dust [11], by and large such events are rare, and the levels of
individual pesticides found in colonies generally low [9, 10, 12]. Considered singly, insecticide
exposures, inside and out of the hive, are typically below the levels thought to have large nega-
tive effects on colony health [13, 14]. The problem is that this expectation is based on sensitiv-
ity of bees to an insecticide in single-toxin bioassays. Single toxin exposures are not realistic
and combinations of pesticides and in-hive medications, all at individually benign concentra-
tions, may not have benign consequences. The routine treatment of bee hives with mixtures of
acaricides and antibiotics, combined with the diversity of pesticides and secondary plant com-
pounds that bees encounter, collect and concentrate in their hive, may pose a greater threat to
bees than predicted from their responses to the individual compounds [7, 8, 15, 16]. To accu-
rately assess the risk posed by pesticides, the synergistic, antagonistic and/or additive effects of
the many xenobiotic chemicals bees encounter must be considered.
Because honey bees are exposed to many different xenobiotics it is impractical to test combi-
nations of all of them to assess the likelihood of adverse interactions. Mullin et al. [6] found
over 121 different pesticides in surveyed colonies; if we were to limit testing of only 2-com-
pound interactions among these 121 pesticides, more than 7,000 tests would be needed to test
all possibilities. If, however, the problem is simplified by testing the effect that pesticides have
on those key metabolic and transport-excretion processes that drive the dynamics of toxin dis-
tribution, metabolism and excretion in bees, we may better predict which compounds are likely
to participate in an adverse synergistic interaction at the individual bee and possibly colony
level [17]. This mechanism-based approach is used in pharmaceutical regulation to identify
potentially dangerous drug-drug and drug-food combinations, focusing on metabolizing
enzymes such as cytochrome P450 (Cyp) enzymes and xenobiotic-handling proteins belonging
to two transporter superfamilies, the ATP Binding Cassette (ABC) and the Solute Carrier
transporters. These mechanisms are targeted because they interact with a wide variety of drugs
and plant compounds and are likely causes of adverse interactions among them [18, 19]. John-
son et al. [7, 20] have discussed the importance of the Cyp enzymes in honey bees, but the roles
of transporters have been neglected. Transporters mediate the movement of xenobiotics
through membranes, expediting the movement of toxins and metabolites towards excretion
and preventing infiltration of sensitive tissues by those compounds. Certain ABC transporters,
in particular the ABC-B (MDR or Multi-Drug Resistance transporters), ABC-C (MRP or mul-
tidrug-resistance associated proteins) and ABC-G subfamilies are likely responsible for multi-
ple chemical interactions in honey bees, because they have diverse substrate ranges including
many pesticides and plant produced chemicals [21–25]. Because we are currently unable to
functionally distinguish these subfamilies in honey bees, we refer here to them collectively as
“MDR transporters”.
An adverse interaction of two chemicals encountered by bees would occur through the inhi-
bition of key metabolic enzymes or transporters by one compound that subsequently reduces
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that protein’s capacity to process subsequent, possibly different, toxic substrates. We propose
methods for determining if a xenobiotic inhibits the function of key transporters. Testing new
or in-use pesticides in combination with standard substrates of detoxification mechanisms can
identify those compounds that inhibit or increase the function of that mechanism. Similarly,
tests using standard inhibitors of these xenobiotic-handling mechanisms can identify which
xenobiotics may be substrates of that mechanism. Substrates and inhibitors of ABC transport-
ers are known from work in mammalian, invertebrate and microbial systems [26–29] and are a
good starting point for finding xenobiotic substrates and inhibitors of those transporters in
bees. Hawthorne and Dively [8] show, for example, that inhibition of honey bee MDR trans-
porters significantly increases honey bee sensitivity to two acaricides (fluvalinate and couma-
phos respectively) indicating that they are substrates of those transporters in honey bees.
Previously, Bain et al. [29] had identified fluvalinate and coumaphos as substrates and/or
inhibitors of the key MDR transporter P-glycoprotein (P-gp). Both fluvalinate and coumaphos
have been widely applied to bee colonies for control of the honey bee parasite Varroa destruc-
tor, and remain among the most common pesticide residues found in colony matrices [6, 30].
In another example, Schrickx and Fink-Gremmels [31] identified oxytetracycline as an inhibi-
tor and/or substrate of mammalian P-gp. This antibiotic, which is applied to bee colonies for
prophylactic treatment of the disease American foulbrood, increased honey bee sensitivity to
fluvalinate and coumaphos, as would be expected if the transporters performed similarly in
mammalian and hymenopteran systems [8].
Two types of assays are typically used for in vivo study of xenobiotic transporter function;
inhibitor assays that sensitize cells or individuals to toxic substrates through chemical disrup-
tion of transporter function and labelled substrate assays which track the differential move-
ment of substrate compounds in the presence and absence of inhibitors. Inhibitor assays are
relatively easy to perform on honey bees and their endpoints (often mortality or dysfunctional
behavior) are easily interpreted. However, even for well-characterized inhibitors and substrates,
it remains possible that they affect more than one detoxification or excretion process. A com-
plementary labeled-substrate assay(s) could help confirm the specificity of an inhibitors effect.
Here we investigate the use of ivermectin as a standard substrate for assessing the function
of MDR transporters in honey bees. Ivermectin is an anthelminthic and acaricidal medication,
with human and veterinary applications. It is known to interact with the multi-drug resistance
(MDR) transporters in the ABC-B and/or ABC-C families of xenobiotic transporters [26, 32–
34]. Ivermectin is a semisynthetic macrocyclic lactone derived from fermentation products of
Streptomyces avermitilis [35] and it targets the glutamate-gated, and to a lesser degree the
GABA-gated chloride channels of the insect nervous system [36, 37]. Although ivermectin is
not applied widely for pest control in crops, several important insecticides, acaricides and nem-
aticides, such as abamectin and emamectin benzoate, share ivermectin’s structural features and
target sites [35]. Abamectin resistance in Drosophila has been shown to be strongly related to
P-gp expression and function [38]. The interaction of MDR transporters with ivermectin
was first noted when a strain of mice lacking the ABC-B transporter P-gp, died following iver-
mectin treatment for parasites [33]. Increased MDR transporter function is also known to con-
tribute to ivermectin resistance in parasitic nematodes, cattle ticks, and head lice [39–42].
Silencing those transporters via RNAi reverses ivermectin resistance in lice [41], further sup-
porting observations that xenobiotic-transporting ABC transporters mediate the sensitivity of
arthropods to ivermectin.
We also test the inhibitory effects of several compounds on honey bee MDR transporters by
measuring changes in honey bee sensitivity to ivermectin after exposure to test compounds.
Ivermectin is toxic to honey bees, so we expect that co-exposure of ivermectin with an MDR
transporter inhibitor will significantly increase sensitivity to this toxin.
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MDR transporters may not act alone to protect bees from ivermectin toxicity. Bees may also
use metabolic enzymes such as esterases and CYP enzymes to metabolize the toxin. Therefore
changes in abundance of those enzymes could also alter honey bees sensitivity to ivermectin
[36]. If ivermectin toxicity is indeed mediated by more than one process in bees, its utility as a
model substrate for identifying candidate inhibitory compounds would be enhanced, at the
expense of knowing which process was most responsible.
In this study, we first assess the dose effect of a standard inhibitor of MDR transporters,
verapamil, on honey bee sensitivity to ivermectin. Verapamil is known to inhibit vertebrate
MDR transporters and in insects has been shown to slow the transmembrane transport of P-gp
substrates across the blood-brain barrier and across Malphigian tubule epithelia [43–45]. It has
been suggested, at least for vertebrate cell lines that as an L-calcium channel blocker verapamil
may contribute to increased sensitivity to xenobiotics in other ways as well [46]. We then test
three compounds, previously shown to interact with MDR transporters in other organisms, for
their potential to synergize ivermectin toxicity; fumagillin, an anti-microbial compound used
to treat honey bee hives for the intestinal parasite Nosema sp., Pristine, a crop fungicide com-
posed of the two active ingredients boscalid and pyraclostrobin used on fruit and nut trees dur-
ing bloom, and quercetin, a plant compound found in pollen and nectar. Fumagillin and
quercetin are known to inhibit the function of mammalian P-gp [47, 48] and boscalid and pyr-
aclostrobin resistance in the fungal plant pathogen botrytis, has been attributed in part to
changes in the MDR transporters of that pathogen, suggesting that the fungicides interact with
those transporters in botrytis [49]. Although bees are not frequently exposed to ivermectin,
any indication that these test compounds inhibit the function of the MDR transporters of bees
by increasing their sensitivity to ivermectin would suggest that exposure to these compounds
may sensitize bees to more common chemicals in the bee environment.
In addition to testing the effects of fumagillin and quercetin on honey bee sensitivity to iver-
mectin, we also tested these compound’s effects on honey bee sensitivity to the neonicotinoid
insecticide acetamiprid. We have previously shown that bees are sensitized to acetamiprid fol-
lowing ingestion of verapamil, suggesting that acetamiprid is a substrate of those transporters
in honey bees [8]. A commonly encountered environmental chemical that inhibits MDR trans-
porters and increases sensitivity of bees to both ivermectin and acetamiprid, could similarly
increase bee’s sensitivity to a broad array of compounds that are also substrates of MDR trans-
porters posing a risk to hive health under field conditions.
The use of bioassays with well-characterized inhibitors and substrates is complemented by
labeled-substrate assays of transporter function. Rhodamine B (RhB) is a fluorescent substrate
of P-gp and possibly other MDR transporters. RhB is used to assess transporter function in
many organisms including insects, bivalves, and fish [50–52]. Given a simple model of RhB
dynamics within a honey bee following orally ingestion of this fluorophore, we expect MDR
transporters in the midgut epithelium to slow the rate of RhB movement into hemolymph and
for those transporters in the Malpighian tubules to remove RhB from hemolymph. Therefore,
we expect hemolymph concentrations of RhB to be higher in bees treated with transporter
inhibitors as a result of reduced transporter function in the midgut and Malpighian tubules
[45, 53–56]. We also expect higher RhB concentrations in the heads (composed largely of brain
and salivary glands) of bees treated with inhibitors because, in addition to higher hemolymph-
mediated exposure, these transporters have key roles in maintaining the blood-brain barrier in
insects, preventing the accumulation of xenobiotics in brain tissue [43, 44, 50].
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Materials and Methods
Honey Bees
Apis mellifera were obtained from hives maintained on the University of Maryland farm in
Beltsville, MD. Hives were maintained by standard bee keeping practices, and kept free of in-
hive medications. Brood frames were taken from hives and emerging bees were collected daily
into 207 ml cages of 15–20 bees and fed 30% sucrose w/v solution. Bees used in bioassays were
3–7 days post-eclosion.
Chemicals
Ivermectin (>95%) was purchased from MP Biomedicals, (Solon, OH), verapamil, quercetin,
Rhodamine B were purchased from Sigma, a formulated solution of acetamiprid (Assail) was a
gift from United Phosphorous Inc. (King of Prussia, PA), and formulated ‘Pristine’ was a gift of
BASF Corp. (Research Triangle Park, NC). Ivermectin, the candidate inhibitors, and verapamil
were fed to bees in a 30% sucrose solution. Quercetin was first dissolved in DMSO in a 50 mM
solution before dilution to 1 mM in a 30% sucrose solution. All other inhibitors were dissolved
in distilled water. Because Pristine is a formulation containing two fungicides, boscalid and
pyraclostrobin, a 50 mM stock was made using the combined molecular weights of the compo-
nents weighted by their relative fraction of the total mass in the formulation.
Inhibitor bioassays
Bees were fed (ad lib.) 1 mM solutions of verapamil, fumagillin, Pristine, or quercetin for 24 h
(in 30% sucrose syrup) and then fed sucrose solutions containing 1 mM of the same test inhibi-
tor and 1 μg/ml ivermectin. Mortality was recorded 24 h after ivermectin exposure for 20–28
replicate cages of bees with approximately 15 bees in each cage. No-inhibitor controls (15
cages) were included in each assay. Subsequently, using the same bioassay protocol, a series of
6 concentrations of ivermectin were used to estimate shifts in the LC50 of ivermectin resulting
from ingestion of the 1 mM inhibitor. Mortality rates for each concentration of ivermectin
were estimated by averaging the mortality of approximately 15 bees contained in each of 4 rep-
licate cages. Similarly, to measure changes in sensitivity to ivermectin at varying dosages of the
inhibitors, 4–12 replicate cages of bees (fewer at extreme dosages, more at intermediates) were
fed a series of concentrations of each inhibitor (0, 0.03, 0.06, 0.125, 0.25, 0.5, 1.0, 2.0 mM) for
24 h, then fed a combination of the same inhibitor dose and 1μg/ml ivermectin solution.
Changes in sensitivity to the neonicotinoid insecticide acetamiprid following pre-treatment
of bees with the inhibitors verapamil, fumagillin and quercetin (1 mM) were tested using a
0.1 μg/μl concentration of the active ingredient in formulated insecticide. Mortality rates for
groups of 5 to 15 bees were estimated by averaging results from12 replicate cages for each
inhibitor–acetamiprid combination. Mortality of bees in 3 cages for each inhibitor–without
insecticide were also recorded.
Analysis. Mortality was estimated as the proportion of bees within a cage that were dead
at 24 or 48 h after treatment with ivermectin. Comparisons of mean mortality among treat-
ments were tested using t-tests. LC50s of ivermectin with inhibitors were estimated using the
ProcProbit procedure in SAS (V. 9.2).
Functional Transport Assays
Cohorts of 10–15 bees in mesh-covered cages (207 ml) were fed 30% sucrose solutions contain-
ing a range of verapamil concentrations (0, 0.05, 0.1, 0.33, 0.66, 1.0 mM) for 24 h. Cohorts were
then shallowly anesthetized by chilling. During recovery, bees were hand-fed 10 μl of RhB
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(0.125 mg/ml) in 30% sucrose syrup, then placed individually into a 15 mL centrifuge tube for
2 h to allow each bee to fully consume the solution. Bees were then returned to their original
cups along with similarly treated cohort members and continued feeding on their assigned
inhibitor treatment ad lib.
Concentrations of RhB were measured in hemolymph, heads, and whole guts from each of
8–15 anesthetized bees, 24 or 48 h after dye consumption. Hemolymph concentrations of RhB
were estimated from 1 μl samples of hemolymph collected from individual bees. Hemolymph
was added to 50 μl 0.01% SDS, mixed thoroughly and transferred to a 96 well plate for mea-
surement of RhB fluorescence. Rhodamine B concentrations in the head were measured by
removal of the head from the body, removal of mandibles and proboscis, and dicing the head
into small pieces with dissecting scissors. The diced tissue was pestle-macerated in a 1.5 ml
tube with 50 μl 0.01% SDS. Into each tube, 200 μl 0.01% SDS and four stainless steel beads (two
1.4 mm and two 2.3 mm) were added and the tubes vortexed for 4 minutes at 3000 RPM with a
0.5 second pulse every 2 s with a Vortex Genie Pulse (Scientific Industries, Bohemia, New
York). Tubes were centrifuged for 240 s at 5000 RPM and RhB fluorescence measured from
50 μl of supernatant. The entire gut of the bees, including Malpighian tubules, was dissected
and crushed with a pestle in a 1.5 ml tube containing 50 μl 0.01% SDS. After addition of 100 μl
0.01% SDS, each sample was vortexed for 5 s before centrifugation (240 s, 5000 RPM) and anal-
ysis of the supernatant solution (50 μl) for RhB fluorescence. Fluorescence of all samples was
measured using a Molecular Devices FilterMax F5 spectrophotometer (excitation 535 nm,
emission 595 nm).
Analysis. To correct for variation in dye consumption by individual bees, fluorescence
measures from hemolymph or head samples of an individual bee were indexed as a fraction of
the combined fluorescence of all three tissues (hemolymph + head + gut) of that bee, relative to
the mean of that variable for the control samples analyzed on the same day.
Tests of the relationship of verapamil concentration fed to bees and the RhB concentrations
in the hemolymph and head tissues were performed using ProcMixed in SAS (V. 9.2). Because
variances differed for those bees treated with low (0.01, 0.05 mM) versus high (0.33, 0.66,
1.0 mM) doses of verapamil, the covariance matrices for those data were estimated separately
using a repeated statement.
Results
Bioassay tests of inhibitors
The 1 μg/ml concentration of ivermectin caused a mean mortality of 0.14 over numerous trials;
significantly greater (p< 0.01) than the sucrose syrup control (0.04) but low enough to demon-
strate additional sensitivity caused by candidate synergists. Verapamil-treated bees were signif-
icantly sensitized to 1 μg/ml ivermectin, with mean mortality increasing to 0.85, as were bees
co-exposed to Pristine (0.82), fumagillin (0.47) and quercetin (0.54) (Fig 1). Inhibitor-only
controls had very low mortality of 0.05, 0.05, 0.01 and 0.02 for verapamil, Pristine, fumagillin
and quercetin, respectively (Table 1).
The LC50 estimate for bees fed ivermectin laced syrup after 24 h was 1.57 μg/ml. Using non-
overlapping 95% confidence intervals as a guide for statistical significance, all of the candidate
inhibitors caused significant shifts towards increased sensitivity of tested bees to ivermectin
(Table 1), with synergism ratios of 2–4 fold for 1 mM inhibitor. Additional assays using a series
of 2-fold dilutions of the inhibitors resulted in gradual declines in sensitivity to 1 μg/ml iver-
mectin (Fig 1), with the lowest concentrations (0.03 or 0.06 mM) showing significantly greater
mortality than ivermectin-only treatments for all 4 inhibitors (Fig 2).
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Acetamiprid assay. Sensitivity to acetamiprid (0.1 μg/μl) was increased by 3 of the inhibi-
tors (Fig 3) and the increases in mortality were similar to those observed for ivermectin. Con-
trol mortality from acetamiprid alone at that concentration was 0.25. We observed increased
mean mortality to 0.95, 0.80 and 0.97 when bees were treated with verapamil, fumagillin and
quercetin, respectively (Fig 3). Mean mortality was very low for 3 replicate cages of bees fed
only verapamil (0.05), fumagillin (0.01) or quercetin (0.07).
Functional assay of transporters using RhB dye
There was a significant increase in hemolymph and head RhB concentrations with increasing
dosages of verapamil after both 24 and 48 h (Table 2, Fig 4). Tissues from verapamil-treated
bees had 2.66–11.72 fold higher hemolymph and 2.28–10.13 fold higher head RhB
Fig 1. Mortality of honey bees (24 h ±SE) pretreated with a series of concentrations of candidate
inhibitors. Bees were fed verapamil, quercetin, fumagillin or Pristine before and during oral exposure to 1 μg/
ml ivermectin.
doi:10.1371/journal.pone.0148242.g001
Table 1. Increased sensitivity of honey bees to ivermectin (1ug/ml) following oral exposure to standard and tested inhibitors (1mM) and LC50 of
ivermectin following treatment of bees with 1 mM inhibitor solution. All inhibitor + ivermectin treatments had significantly higher mean mortality than the
ivermectin treatment (p < 0.0001).
Treatment Mortality (SE) 1 μg/ml IVM and 1mM Inhibitor LC50 (μg/ml) 95%CI Synergism Ratio (LC50 relative to IVM)
Ivermectin (IVM) 0.14 (0.02) 1.57 1.38–1.80 1.00
IVM + Verapamil 0.85 (0.03) 0.38 0.01–0.67 4.13
Verapamil 0.05 (0.02)
IVM + Pristine 0.82 (0.03) 0.57 0.34–0.74 2.75
Pristine 0.05 (0.03)
IVM + Fumagillin 0.47 (0.04) 0.86 0.47–1.25 1.83
Fumagillin 0.01 (0.01)
IVM + Quercetin 0.54 (0.05) 0.61 0.41–0.77 2.57
Quercetin 0.02 (0.02)
doi:10.1371/journal.pone.0148242.t001
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concentrations than control bees after 24 h (Fig 4). Mean RhB concentrations in hemolymph
were significantly lower after 48 h when compared to 24 h measures (Table 2). There was a
similar, but non-significant trend for RhB concentration in head tissue. It may be that RhB is
cleared from the hemolymph more rapidly than brain tissue, perhaps through the normal func-
tion of the Malpighian tubules resulting in reduced RhB in hemolymph after 48 h.
Discussion
We show that ivermectin is an effective test-substrate for identifying compounds that inhibit
the function of MDR transporters in honey bees by sensitizing bees to ivermectin with the
MDR transporter-inhibitor verapamil. This interaction has previously been observed with
mosquitoes [57], parasitic nematodes [39], cattle ticks [58] and human body lice [41]. We also
show that reductions in the function of MDR transporters can be measured by increased accu-
mulation of the fluorescent substrate RhB in hemolymph and head tissues of bees, similar to
previously observations in Drosophila, aquatic insects, mollusks, and many cell-transport
assays [50, 59, 60].
Many agricultural pesticides are known to interact with MDR transporters as substrates or
inhibitors including members of most classes of insecticides and fungicides [21]. We tested sev-
eral compounds that honey bees commonly encounter, all previously shown to interact
with MDR transporters in other systems, and found them to increase bee’s sensitivity to iver-
mectin and the neonicotinoid insecticide acetamiprid. We are especially interested in the MDR
Fig 2. Mean 24 hmortality (±SE) of honey bees fed 1 μg/ml ivermectin treated with low concentrations
of inhibitors. Bees fed Pristine (Prist), quercetin (Querc), fumagillin (Fumag) and verapamil (Verap) in
sucrose syrup. All inhibitor/doses shown had significantly greater mortality than the ivermectin-only control
(P < 0.002).
doi:10.1371/journal.pone.0148242.g002
Fig 3. Increased sensitivity of honey bees to the neonicotinoid insecticide acetamiprid.Mean mortality
(±SE) of honey bees fed 0.1 μg/μl acetamiprid with 1 mM solutions of inhibitors in sucrose syrup. All inhibitor-
acetamiprid combinations had significantly greater 24 h mortality than the acetamiprid-only control
(P < 0.0002).
doi:10.1371/journal.pone.0148242.g003
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transporters here because their substrate promiscuity will likely cause numerous adverse inter-
actions among xenobiotics in bees’ environments when the transporters are inhibited. Ivermec-
tin served here as an effective model substrate for analysis of MDR transporter-mediated
inhibition of detoxification and excretion systems in honey bees. The increased sensitivity of
bees to ivermectin following exposure to Pristine, fumagillin, and quercetin is evidence that
those compounds are interacting with the MDR transporters in bees to synergize the toxicity of
ivermectin, although other mechanisms cannot be excluded. These inhibitors may similarly
sensitize bees to other xenobiotics that are substrates of these transporters. Indeed, fumagillin,
quercetin and verapamil each sensitized bees to the neonicotinoid insecticide acetamiprid, a
toxin previously shown to be a substrate of the MDR transporters in bees [8]. It is important to
note that because ivermectin is not a crop pesticide, it is not a significant threat to honey bees,
although two similar insecticides (abamectin and emamectin benzoate) are agricultural/for-
estry insecticides and warrant testing. In most of our bioassays candidate inhibitors were tested
at concentrations higher than those likely experienced by bees in the field. However, trials of
much lower, possibly field-relevant (ca. 0.05x) concentrations of the inhibitors show that they
continue to increase honey bee sensitivity to ivermectin (Fig 2). Similarly, the dosage of aceta-
miprid used here is greater than that typically encountered by foraging bees and any conclu-
sions about honey bee risk to acetamiprid exposure requires additional research. Our objective
here is simply to assess the suitability of ivermectin as a surrogate for acetamiprid and perhaps
other formulated pesticides that are, despite very different chemistries and target sites, also sub-
strates of honey bee MDR transporters.
Fumagillin, Pristine and quercetin were tested here because they have previously been
shown to interact with MDR transporters and they are commonly found in a bees’ environ-
ments. The observation that these compounds synergize the toxicity of ivermectin and aceta-
miprid suggests that they pose risks for bees when exposed to other xenobiotics. Fumagillin is
Table 2. Transporter function assays. Bees treated with a series of dosages of the MDR transporter-inhibitor verapamil before and after ingestion of the
fluorescent substrate Rhodamine B solution, and assayed at two times (24 and 48 h post ingestion) show greater fluorescence at increased verapamil con-
centrations in both tissues.
Tissue Effect df F P-value
Hemolymph Time 1,83 5.57 0.021
Dose 1,83 61.51 <0.0001
Dose × Time 1,83 0.07 0.80
Head Effect df F P-value
Time 1,83 1.10 0.30
Dose 1,83 78.21 <0.0001
Dose × Time 1,83 0.05 0.82
doi:10.1371/journal.pone.0148242.t002
Fig 4. Rhodamine B fluorescence of head and hemolymph tissues.Mean fluorescence relative to no-
verapamil controls (24 and 48 h post feeding) at a series of verapamil concentrations.
doi:10.1371/journal.pone.0148242.g004
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widely used to treat and prevent Nosema sp. infection of bees in North America, but its use is
not permitted in the EU [61]. It is applied to hives in the fall and again in the spring, often in a
heavy sugar syrup solution [62]. Although the 1 mM concentration used in most of our experi-
ments is higher than the label-rate field exposures of bees (field rates estimated from label are
0.054 mM), bees may concentrate and store the fumagillin-laced syrup as honey resulting in a
prolonged exposure at a range of concentrations. Dosages of fumagillin as low as 0.03 mM,
clearly within the range of expected exposures of treated bee hives, increase sensitivity of bees
to ivermectin (Fig 2). Because fumagillin is widely used, most commonly by commercial bee
keepers, and is likely an inhibitor of the MDR transporters in bees, it may alone or in combina-
tion with other inhibitors create significant sensitivity to otherwise tolerable dosages of pesti-
cides or other toxins which are substrates of the transporters. Johnson et al. [63] also observed
increased honey bee sensitivity to tau-fluvalinate following treatment with fumagillin. The sea-
sonal pattern of fumagillin hive treatments coincides with application of oxytetracycline, also
shown to sensitize bees to pesticides; also potentially through inhibition of MDR transporters
[8]. Further testing is required to confirm that field-relevant dosages of fumagillin have a sig-
nificant impact on sensitivity to field-relevant concentrations of pesticides.
Pristine is a fungicide blend containing two active compounds and other ingredients. Pris-
tine is commonly applied at blossom to many crops including almonds and tree-fruits, assuring
honey bee exposure. Residues of the component fungicides have been recovered from hives [5,
64], but increased mortality of bees exposed to Pristine alone has not been reported. Johnson
et al. [63] showed a 3-fold synergism of the pyrethroid tau-fluvalinate following exposure to
the components of Pristine. Because fluvalinate is likely a substrate of the MDR transporters
[8, 29], this interaction may be due to a competitive inhibition of the transporters by the fungi-
cides. Johnson et al. [63] tested the components of Pristine (pyraclostrobin and boscalid) sepa-
rately and found that both sensitized bees to fluvalinate, pyraclostrobin more so. Additional
testing needs to be done on individual components of this pesticide formulation to determine
which are causing the effects observed here, and to evaluate effects at dosages to which bees
are exposed under field conditions. If Pristine or one of its components contributes to the
inhibition of MDR transporters as we suspect from these data; the exposed bee colonies
could become more sensitive to an array of pesticides that are substrates of the bees MDR
transporters.
Quercetin is a commonly encountered secondary plant compound (flavonoid), found in
nectar and pollen of many plants and in the propolis and honey of bee hives. It is an inhibitor
of MDR transporters in assays of mammalian and insect cells and nematodes [65, 66] and it
may also interact with Cyp metabolic enzymes [67]. The amount of quercetin in nectar and
pollen varies among crops [68], suggesting that sensitivity of bees to toxic pesticides may vary
with forage characteristics.
In addition to identifying some compounds that may increase honey bee sensitivity to insec-
ticides, this study illustrates a strategy for streamlining the identification of dangerous combi-
nations of chemicals among many possibilities, as is the case with honey bees. As an example,
instead of testing candidate combinations one-by-one for adverse interactions among all of the
potential candidates, we can now test an entire category of potential interactions (those medi-
ated by MDR transporters) using increased sensitivity to ivermectin as an indication of MDR
transporter inhibition. When assessing the potential for adverse interactions caused by multi-
ple candidates, this strategy reduces the number of tests dramatically, screening pairwise inter-
actions mediated by this mechanism in N tests for N candidate compounds instead of NN1
2
 
tests, a potentially very large difference. To test 10 compounds for adverse interactions with
MDR transporters, one can test for those interactions in 10 instead of 45 tests, with additional
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testing of those showing significant synergistic effects if desired. If testing 100 compounds, it
would be only 100 tests versus ca. 4,950 tests. This strategy substantially increases the practical-
ity of assessing the risk of adverse interactions of combinations of agricultural chemicals to
honey bees.
Clearly, metabolic mechanisms also mediate harmful pesticide interactions in bees and sim-
ilar assays for the major classes of metabolic enzymes that may also have wide substrate ranges
could be developed [63]. Interestingly, many pharmaceutical substrates of MDR transporters
also interact with the Cyp metabolic enzymes [18, 19]. Therefore, use of ivermectin, or a similar
substrate, as a test for transporter function, may identify compounds that also interact with
metabolic enzymes.
Current assessment of pesticide risks to honey bees in the U. S. and Europe does not con-
sider the altered sensitivity that would occur following exposure to combinations of pesticides.
Given the diverse collection of compounds to which bees are exposed as a result of their forag-
ing and food storage habits and veterinary treatments, it is clearly impractical to require assess-
ment of a new product in combination with all other compounds that bees are likely to
encounter. Mechanism-based strategies for simplifying the assessment of adverse chemical
interactions such as described here could improve our ability to identify those combinations
that pose significantly greater risk to bees and perhaps improve the risk assessment protocols
for honey bees and similar sensitive species.
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